Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Mallinckrodt
Daiichi Sankyo
Medtronic
Cipla
Merck
Chinese Patent Office
US Army
Express Scripts
Accenture

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,993,520

« Back to Dashboard

Which drugs does patent 8,993,520 protect, and when does it expire?

Patent 8,993,520 protects AXIRON and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 8,993,520
Title:Method and composition for transdermal drug delivery
Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
Inventor(s): Dipietro; Tony (Victoria, AU), Humberstone; Andrew (Victoria, AU), Gonda; Igor (South Yarra, AU), Watkinson; Adam (Victoria, AU), Setiawan; Kerrie (Victoria, AU), Wilkins; Nina (Victoria, AU)
Assignee: Acrux DDS Pty Ltd (West Melbourne, Victoria, AU)
Application Number:12/823,448
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Device;

Drugs Protected by US Patent 8,993,520

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No ➤ Subscribe ➤ Subscribe A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,993,520

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2005902902Jun 3, 2005

Non-Orange Book US Patents Family Members for Patent 8,993,520

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,435,944 Method and composition for transdermal drug delivery ➤ Subscribe
9,180,194 Method and composition for transdermal drug delivery ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,993,520

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 563946 ➤ Subscribe
Mexico 2007015255 ➤ Subscribe
South Korea 20130114229 ➤ Subscribe
South Korea 20080033232 ➤ Subscribe
Japan 2013237690 ➤ Subscribe
Japan 5401092 ➤ Subscribe
Japan 2008542306 ➤ Subscribe
Spain 2607454 ➤ Subscribe
European Patent Office 1896038 ➤ Subscribe
Eurasian Patent Organization 019214 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
QuintilesIMS
Cipla
Covington
Cantor Fitzgerald
UBS
US Department of Justice
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot